Abstract
Although prodromal symptoms of psychosis have long been recognized, the clinical management of psychotic disorders conventionally begins at the first episode of frank psychosis, and, until recently, the period immediately preceding the first episode received relatively little attention. Over the last fifteen years, there has been increasing academic and clinical interest in people presenting with potentially prodromal symptoms. This clinical syndrome has been termed an “At Risk Mental State”, and operationalised criteria, the “Ultra High Risk (UHR)”, or “Clinical High Risk” criteria, have been developed to identify the syndrome. We will review here the mainstreams of the UHR paradigms focusing on the conceptual basis, potentials and limtations in current psychiatric research.
Keywords: Psychosis, schizophrenia, prodrome, At Risk Mental State, Ultra High Risk (UHR), Clinical High Risk, subthreshold, depression, mania, Risk Syndrome
Current Pharmaceutical Design
Title: The Ultra High Risk Approach to Define Psychosis Risk
Volume: 18 Issue: 4
Author(s): Alison R. Yung, Paolo Fusar-Poli and Barnaby Nelson
Affiliation:
Keywords: Psychosis, schizophrenia, prodrome, At Risk Mental State, Ultra High Risk (UHR), Clinical High Risk, subthreshold, depression, mania, Risk Syndrome
Abstract: Although prodromal symptoms of psychosis have long been recognized, the clinical management of psychotic disorders conventionally begins at the first episode of frank psychosis, and, until recently, the period immediately preceding the first episode received relatively little attention. Over the last fifteen years, there has been increasing academic and clinical interest in people presenting with potentially prodromal symptoms. This clinical syndrome has been termed an “At Risk Mental State”, and operationalised criteria, the “Ultra High Risk (UHR)”, or “Clinical High Risk” criteria, have been developed to identify the syndrome. We will review here the mainstreams of the UHR paradigms focusing on the conceptual basis, potentials and limtations in current psychiatric research.
Export Options
About this article
Cite this article as:
R. Yung Alison, Fusar-Poli Paolo and Nelson Barnaby, The Ultra High Risk Approach to Define Psychosis Risk, Current Pharmaceutical Design 2012; 18 (4) . https://dx.doi.org/10.2174/138161212799316299
DOI https://dx.doi.org/10.2174/138161212799316299 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endothelial Dysfunction, Obesity and Insulin Resistance
Current Vascular Pharmacology Chondroitin Sulfate Glycosaminoglycans for CNS Homeostasis-Implications for Material Design
Current Medicinal Chemistry Anticholinergic Burden Among Hospitalised Older Adults with Psychiatric Illnesses- A Retrospective Study
Current Drug Safety Silymarin Extends Lifespan and Reduces Proteotoxicity in C. elegans Alzheimer’s Model
CNS & Neurological Disorders - Drug Targets Psoriasis and Atherosclerosis: Is There a Need For Novel Biomarkers Assessing Cardiovascular Risk?
Current Pharmaceutical Design Sleep-Related Disorders, Diabetes and Obesity: Understanding the Facts
Current Respiratory Medicine Reviews Can Apolipoproteins and Complement Factors be Biomarkers of Alzheimer’s Disease?
Current Alzheimer Research Acetylcholinesterase (AChE) - Amyloid-β-Peptide Complexes in Alzheimers Disease. The Wnt Signaling Pathway
Current Alzheimer Research Possible Involvement of Programmed Cell Death Pathways in the Neuroprotective Action of Polyphenols
Current Alzheimer Research Bioinformatic Analysis Reveals Key Genes and Pathways in Aging Brain of Senescence-accelerated Mouse P8 (SAMP8)
CNS & Neurological Disorders - Drug Targets Induced Adaptive Resistance to Oxidative Stress in the CNS: A Discussion on Possible Mechanisms and Their Therapeutic Potential
Current Drug Metabolism Effects of Snake Venom Polypeptides on Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Clinical Importance of Assessment of Type 2 Diabetes Mellitus with Visceral Obesity. A Japanese Perspective
Current Diabetes Reviews Late Onset Alzheimer’s Disease: Novel Clinical Prospects for the Future
Current Neurovascular Research The Role of Minocycline in Ischemia-Reperfusion Injury: A Comprehensive Review of an Old Drug with New Implications
Recent Patents on Cardiovascular Drug Discovery Haptoglobin Phenotype May Alter Endothelial Progenitor Cell Cluster Formation in Cerebral Small Vessel Disease
Current Neurovascular Research AMPA Receptor Potentiators: Application for Depression and Parkinsons Disease
Current Drug Targets Parkinson’s Disease and Alpha-Synucleinopathies: from Arising Pathways to Therapeutic Challenge
Central Nervous System Agents in Medicinal Chemistry Processing of Amyloid Precursor Protein and Amyloid Peptide Neurotoxicity
Current Alzheimer Research Future Targets in Endothelial Biology: Endothelial Cell to Mesenchymal Transition
Current Drug Targets